Portneuf Heart and Vascular Institute (PHVI) in Pocatello, Idaho has been at the forefront of minimally invasive heart surgery since performing the first TAVR heart surgery in 2017. In May 2024, PHVI began utilizing the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system, making them one of the first in the region to do so. The new system offers benefits such as larger coronary access, increased catheter maneuverability, excellent hemodynamics, and durability.
Dr. Jacob DeLaRosa, Chief of Cardiovascular Surgery at PMC, expressed his trust in the Evolut FX TAVR platform, which has been used in TAVR procedures at the institute for several years. With roughly 270,000 people in the US diagnosed with symptomatic severe aortic stenosis each year, this technology is crucial in improving the quality of life for those affected by this condition.
Without treatment, severe aortic stenosis can lead to heart failure within two years for 50% of patients. PHVI’s adoption of the Evolut FX+ TAVR system showcases their dedication to enhancing cardiac care for patients with heart valve disease. If you or someone you know has been diagnosed with symptomatic severe aortic stenosis, speaking with a doctor about the possibility of a TAVR procedure may be a beneficial option. More information can be found at Portneuf.org/hearts.
